Vaporox reported raising $4.93 Million in an initial SEC Form D filing, from an offering of $280,000

Company

Location

About

Non-healing skin wounds impose enormous costs in both money and human suffering. For example, diabetic foot ulcers (DFUs) force 108,000 lower limb amputations in the U.S. annually, and generate economic costs estimated at $14.8 billion/year. Vaporox, Inc.’s Vaporous Hyperoxia Therapy (VHT™), a new, patented, and FDA-510K-cleared technology, offers a breakthrough in treating 7 different types of skin wounds, including DFUs and pressure ulcers (bed sores). Real world data from observational studies show that VHT can heal 90.7% of DFUs that had previously resisted standard wound care treatment, and at much lower cost than less-effective methods. VHT employs ultrasonic waves to create microscopic particles composed of water and an anti-microbial. It then cyclically delivers those particles and oxygen-enriched air to the treatment site, where they penetrate into the recesses of the skin or wound, and ultimately through cell walls. VHT is both more effective and more comfortable for patients than existing technologies. Vaporox plans to begin a new round of field trials focused on healing DFUs and pressure ulcers in early 2019.